Arovella Therapeutics Limited

As of June 30, 2026, Arovella Therapeutics Limited carries a market capitalization of 74.95M, placing it among publicly traded companies globally. Its enterprise value stands at 60.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Arovella Therapeutics Limited's next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2026, Arovella Therapeutics Limited has 1.21B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Arovella Therapeutics Limited maintains a current ratio of 17.51, meaning it holds 17.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Arovella Therapeutics Limited posted a negative return on equity (ROE) of -40.41, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.78, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Arovella Therapeutics Limited's stock has declined approximately 44.94% over the past 52 weeks. The 50-day moving average sits at 0.06, while the 200-day moving average is 0.07.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -11.10M, while operating income came in at -11.21M.

These figures are as of June 30, 2026. Total book value stands at 14.15M, with working capital of 13.82M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield is negative at -0.65, meaning Arovella Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Arovella Therapeutics Limited's most recent stock split took place on July 7, 2020 with a 61:72 split ratio.